

### Remarks

Claims 1-16 are pending in this application. Claims 1-11 have been amended. Claims 14-16 have been added. No new matter has been added.

By way of this preliminary amendment, claims 1-11 have been amended. These claim amendments are being made solely for purposes of placing the claims in a format appropriate for U.S. prosecution. Applicants submit that the amendments do not change the scope of the claims as originally filed. Such amendments are therefore made to address formalities in the claim format and are not related to the patentability of the subject matter of the claims. No new matter was added by way of these claim amendments.

One typographical error has been corrected in claim 10 by deleting one extra bracket ")".

The subject matter of amended claims 3 and 10 was disclosed in the specification as filed on page 5, lines 10-12.

The subject matter of new claim 14 was disclosed in the specification as filed on page 5, lines 10-13.

The subject matter of new claim 15 was disclosed in the specification as filed on page 9, first paragraph.

The subject matter of new claim 16 was disclosed in the specification as filed on page 9, first paragraph.

In view of the above amendments and arguments, this application is deemed to be in a form suitable for US prosecution.

Respectfully submitted,



---

Dr. Tilman Breitenstein  
Limited Recognition Under 37 CFR § 11.9(b)  
Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516-4175

Phone: (203) 812-2226  
Date: June 10, 2005